Seroquel maker to pay $5.5M in latest settlement related to off-label use of the antipsychotic drug

Share this article:

Drugmaker AstraZeneca recently settled a lawsuit with the state of Kentucky over allegations of improperly marketing its atypical antipsychotic drug Seroquel. Under the settlement, the London-based pharmaceutical company will pay the Bluegrass State $5.5 million.

AstraZeneca improperly marketed the schizophrenia and bipolar disorder drug for off-label uses, including treatment of dementia and Alzheimer's disease, according to the state's attorney general, Jack Conway. As of August 2004, about 15% of Seroquel users in Kentucky were older than 65, but the drug company had not established Seroquel's “safety or effectiveness” for this group, according to the attorney general.

A spokesman for AstraZeneca said the company denies the allegations and settled with Kentucky to avoid a lengthy and expensive legal battle, according to the Bureau of National Affairs.

This is the latest example of AstraZeneca settling a suit related to marketing Seroquel for off-label uses. The company paid out $520 million in a federal settlement in 2010 and $68.5 million in a settlement involving 37 states in 2011.

Seroquel was the antipsychotic drug most often given to nursing home residents as of 2010, according to a recently published study.

Share this article:

More in News

CMS needs to get nursing home staffing information directly from payroll systems, Congressional leaders say

CMS needs to get nursing home staffing information ...

Federal regulators should start collecting nursing home staffing information directly from payroll systems as soon as possible, members of the Congressional Seniors Task Force said in a letter to a ...

Male CNA who wears women's clothing can pursue charges that nursing home ...

A Texas certified nursing assistant can continue to pursue charges that his former nursing home employer has made false, defamatory statements about him in the job referral process, a federal court recently ruled.

High-profile consumer advocacy group sues over broken Medicare appeals process

Long-term care providers have been outspoken in their criticism of the Medicare appeals process, which has all but ground to a halt. Now a class-action lawsuit says Medicare beneficiaries also are being harmed by the excessively long delays.